Goodbye to high cholesterol? Moncyte is developing a solution

A recently established spinout is aiming to help people reach a good cholesterol level as quickly as possible. The innovation is based on research conducted at the University of Helsinki.

Cholesterol-lowering drugs are the most widely prescribed medicines in the world, but most patients with high cholesterol do not reach their target cholesterol levels – at least not quickly. This is due to there currently not being an effective way to determine which patients need more effective drug therapies. 

However, a solution is in the offing. Moncyte, a recently established spinout of the University of Helsinki, has developed a method providing information about the cellular mechanisms that influence the effectiveness of cholesterol-lowering drugs in individual patients. 

The patented technology is significantly different from other existing diagnostic tests that measure blood cholesterol concentration. The innovation is based on how cholesterol is transported and processed in human cells. Since the most important cholesterol-lowering treatments function at the cellular level, this type of research is essential to identifying opportunities for developing novel drugs and personalised therapies for high cholesterol.

“The journey of developing Moncyte from a university research project into a biotech company has been exciting, and we believe our unique test can make a real difference in improving the health of patients with high cholesterol,” says the company CEO, Tamara Alagirova.

Good cholesterol levels reduce the risk of the onset of cardiovascular diseases

Moncyte’s technology also reduces the need for various experiments leading to more patients receiving effective drug treatment. This will enable patients to reach their personal cholesterol goals faster and reduce their risk of cardiovascular diseases, ultimately saving lives and money.

Moncyte’s technology can be applied in the clinic, health centres, clinical studies and research centres.

“It has been inspiring to support the Moncyte team in transforming their research-based invention into commercially potential novel technology and finally into a spinout. We are eager to follow this ambitious team’s path towards the markets and wish the company the best of luck on their business journey,” says Kajsa Kajander, interim CEO of Helsinki Innovation Services Ltd.


Moncyte, a University of Helsinki spinout company, was founded by Simon Pfisterer, CSO, research group leader at the Department of Anatomy at the University of Helsinki, and Tamara Alagirova, CEO, who has wide experience in pharma, medical devices, surgical implants, and diagnostics. 

Helsinki University Funds is one of the cofounders of Moncyte and has worked closely with Helsinki Innovation Services Ltd., the University’s technology transfer company, to establish this new spinout. Helsinki University Funds, together with the founding team and one angel investor, provided the first pre-seed round for the company.  Moncyte brings the number of spinout companies established at the University of Helsinki since 2015 to 24.

Further information

Tamara Alagirova, CEO, Moncyte Oy,


Moncyte offers technology that generates unique data points for pharmaceutical companies. Moncyte performs an in-depth analysis and quantification of cellular mechanisms, shedding light on why some people respond differently to cholesterol-lowering drugs. This makes treatment more impactful while opening new ways for personalised medicine for doctors and patients.

Helsinki Innovation Services

Helsinki Innovation Services Ltd is a technology transfer and research commercialisation company owned by the University of Helsinki. It supports the University’s top research teams as they turn their research-based inventions into commercially flourishing businesses. Experts at Helsinki Innovation Services evaluate the commercial significance of research-born ideas and inventions and assist researchers with matters such as finding funding for the preparation of commercialisation, out-licensing technologies, ensuring patent protection and establishing spinouts. Helsinki Innovation Services also builds bridges between spinouts and investors, supporting the organisation of the former.